Korro Bio (KRRO) EBT (2018 - 2026)

Korro Bio (KRRO) has reported EBT for 9 consecutive years, with -$18.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 27.01% year-over-year to -$18.8 million; the trailing twelve-month figure through Jun 2026 stood at -$107.0 million (down 17.17% YoY), and the FY2025 full-year result was -$117.8 million, down 41.1% from the prior year.
• EBT improved to -$18.8 million in Q2 2026 per KRRO's latest filing, from -$19.5 million in the prior quarter.
• Across five years, EBT topped out at $6.2 million in Q4 2022 and bottomed at -$50.6 million in Q4 2025.
• Historically, EBT has averaged -$21.0 million across 5 years, with a median of -$20.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBT surged 128.86% in 2022, then sank 509.77% in 2023.
• Over 5 years, EBT stood at $6.2 million in 2022, then tumbled by 509.77% to -$25.4 million in 2023, then climbed by 16.79% to -$21.2 million in 2024, then plunged by 139.17% to -$50.6 million in 2025, then jumped by 62.83% to -$18.8 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$18.8 million, -$19.5 million, and -$50.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.